ArticlePain2008
Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan.
Article in Pain, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Review
- Targeting GCell reports. Medicine · 2026Article
- Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.International journal of pharmaceutics · 2026Article
- Discovery of a functionally selective serotonin receptor (5-HTScience advances · 2025Article
- Collaborative action between noradrenergic and serotoninergic systems in peripheral antinociception in mice.Journal of biosciences · 2024Article
- Inflammation induces developmentally regulated sumatriptan inhibition of spinal synaptic transmission.British journal of pharmacology · 2020Article
- Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model.Inflammopharmacology · 2019Article
- A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain.Scientific reports · 2018Article
- A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.Pharmaceutical research · 2016Article
- Mechanisms mediating nitroglycerin-induced delayed-onset hyperalgesia in the rat.Neuroscience · 2016Article
- Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.Frontiers in pharmacology · 2015Article
- Serotonin, 5HT1 agonists, and migraine: new data, but old questions still not answered.Current opinion in supportive and palliative care · 2014Review
- Article
- Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- 5-HT(1B) receptors inhibit glutamate release from primary afferent terminals in rat medullary dorsal horn neurons.British journal of pharmacology · 2012Article
- What would 5-HT do? Regional diversity of 5-HT(1) receptor modulation of primary afferent neurotransmission.British journal of pharmacology · 2012Article
- The complex actions of sumatriptan on rat dural afferents.Cephalalgia : an international journal of headache · 2012Article
- Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn.British journal of pharmacology · 2012Article
- Minocycline markedly reduces acute visceral nociception via inhibiting neuronal ERK phosphorylation.Molecular pain · 2012Article
- Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat.Neuroscience · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Sumatriptan and the other triptan drugs target the serotonin receptor subtypes1B, 1D, and 1F (5-HT(1B/D/F)), and are prescribed widely in the treatment of migraine. An anti-migraine action of triptans has been postulated at multiple targets, within the brain and at both the central and peripheral terminals of trigeminal "pain-sensory" fibers. However, as triptan receptors are also located on "pain-sensory" afferents throughout the body, it is surprising that triptans only reduce migraine pain in humans, and experimental cranial pain in animals. Here we tested the hypothesis that sumatriptan can indeed reduce non-cranial, somatic and visceral pain in behavioral models in mice. Because sumatriptan must cross the blood brain barrier to reach somatic afferent terminals in the spinal cord, we compared systemic to direct spinal (intrathecal) sumatriptan. Acute nociceptive thresholds were not altered by sumatriptan pre-treatment, regardless of route. However, in behavioral models of persistent inflammatory pain, we found a profound anti-hyperalgesic action of intrathecal, but not systemic, sumatriptan. By contrast, sumatriptan was completely ineffective in an experimental model of neuropathic pain. The pronounced activity of intrathecal sumatriptan against inflammatory pain in mice raises the possibility that there is a wider spectrum of therapeutic indications for triptans beyond headache.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.